What it’s for
- Insomnia with trouble falling or staying asleep
A prescription sleep medicine, sold as Belsomra, that blocks the brain's orexin wake signal.
Purpose, evidence and practical considerations.
Randomized trials show modest improvements in falling and staying asleep in adults with insomnia. Next-day drowsiness is the main practical drawback. Claims that it protects against dementia by improving brain waste clearance are an area of early research, not an established benefit.
Confidence: strong
The US label warns of next-day impairment of alertness and driving, especially at 20 mg or with less than a full night in bed; complex sleep behaviours such as sleep-driving; sleep paralysis, hypnagogic hallucinations and cataplexy-like weakness; and worsening depression or suicidal thinking. It must not be combined with alcohol. It is contraindicated in narcolepsy, and strong CYP3A inhibitors are not recommended with it.
Suvorexant blocks the binding of the wake-promoting neuropeptides orexin A and orexin B to the OX1 and OX2 receptors. Lowering orexin signalling is presumed to reduce the drive to stay awake, rather than broadly sedating the brain as GABA-acting hypnotics do.
Regulatory status: prescription medication; US Schedule IV controlled substance
The evidence on this page does not automatically apply to:
How people use it, with their schedules, context and original sources.
mostly because Alzheimer's runs in his family; he said it helps his sleep
Brand variants reported in public protocols. Private entries are excluded, and inclusion is not an endorsement.
These share a protocol with this intervention. This does not establish that they work together or are suitable alternatives.